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Flattening filter-freeOptimizing irradiation protocols for pregnant women is challenging, because there are few cases and a
dearth of fetal dosimetry data. We cared for a 36-year-old pregnant woman with tongue cancer. Prior
to treatment, we compared three intensity-modulated radiation therapy (IMRT) techniques, including
helical tomotherapy, volumetric arc therapy (VMAT), and flattening-filter free VMAT (FFF-VMAT) using
treatment planning software. FFF-VMAT achieved the minimum fetal exposure and was selected as the
optimal modality. We prescribed 66 Gy to the involved nodes, 60 Gy to the tumor bed and ipsilateral
neck, and 54 Gy to the contralateral neck over 33 fractions. To confirm the out-of-field exposure per frac-
tion, surface doses and the rectal dose were measured during FFF-VMAT delivery. Postoperative chemora-
diotherapy was delivered using IMRT and a cisplatin regimen. Without any shielding, the total fetal dose
was 0.03 Gy, within the limits established by the ICRP. A healthy girl was born vaginally at 37 weeks’
gestation.
 2019 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The rare coincidence of cancer and pregnancy is challenging to
treat given the dearth of data on fetal dosimetry. Oral cancer
accounts for <2% of all cancers during pregnancy, and there is no
standard treatment approach [1]. For non-pregnant patients with
negative prognostic factors, including surgical margin positivity
and extracapsular lymph node extension, postoperative chemora-
diotherapy (POCRT) is indicated as adjuvant treatment. Because
POCRT may incur risk to the fetus [2], minimizing fetal dose is vital.
Several intensity-modulated radiotherapy (IMRT) techniques
can reduce fetal dose. Although IMRT is excellent at sparing organs
at risk (OARs) in head and neck cancers, it has scatter and leakage
issues that must be dealt with [3]. Some studies have focused on
the flattening-filter free mode (FFF) of a linear accelerator to
reduce OAR dose [4,5].Herein, we present our phantom simulations and describe our
treatment of a pregnant woman who underwent POCRT for tongue
cancer.2. Case report
A 36-year-old primipara presented with a nodule at the tongue
tip, and reported increasing pain. Biopsy and multiple imaging
tests revealed a squamous cell carcinoma with involvement of
multiple ipsilateral cervical lymph nodes (Fig. 1). This cT2N2bM0
case was discussed in depth at a multidisciplinary tumor board,
and it was decided that surgery should be performed during preg-
nancy. At the 17th week of pregnancy, partial glossectomy and
lymph node dissection (bilateral levels I–III) were performed.
There were no severe operative complications. Pathology con-
firmed extracapsular lymph node extension. To reduce the risk of
locoregional failure, our tumor board decided that POCRT during
pregnancy was justified. Written informed consent from the
patient and her family was obtained before the initiation of POCRT.
Concomitant with the radiotherapy, the patient was scheduled
to receive intravenous tri-weekly cisplatin at 80 mg/m2 based on
Fig. 1. Pretreatment CT scan. Squamous cell carcinoma in the tongue with involvement of multiple ipsilateral cervical lymph nodes (arrows).
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nancy [6].2.1. RT planning and optimal modality selection
Using a thermoplastic mask for immobilization, a planning CT
dataset was acquired using a 16-detector scanner (Toshiba Aquil-
ion LB, Toshiba Medical Systems, Otawara, Japan). For IMRT plan-
ning, CT image data were reconstructed as 2 mm sections and
were then sent to our treatment planning systems (TPS).
To find an optimal modality for fetal dose reduction during
IMRT of the pregnant patient, a fetal dosimetric comparison was
performed among helical tomotherapy (HT), single-arc volumetric
arc therapy (VMAT), and FFF-VMAT.
Using 6 MV photon beams modulated by binary multileaf colli-
mation, the HT plan was simulated on the Tomotherapy Planning
Station software (v5.1.1.6, Accuray Inc. Sunnyvale, CA, USA). The
VMAT and FFF-VMAT plans were created on the Pinnacle3 TPS
(v9.10, Philips Medical Systems, Fitchburg WI, USA), with maxi-
mum dose rates of 600 and 1,500 MU/min, respectively. One com-
plete arc was used for both VMAT techniques using the Agility
MLC, achieving <0.5% leakage.
Using a simultaneous integrated boost method, we prescribed
66 Gy to the involved nodes, 60 Gy to the tumor bed and ipsilateral
nodal levels I–V, and 54 Gy to the contralateral levels I–V over 33
fractions. The planning target volume (PTV) was defined by adding
a 3-mm margin in all directions. Dose constraints for the PTV and
OARs were: median values of D2% (maximum dose received by 2%
of the PTV), D10% and D50% were <115%, 110%, and 105% of the
prescribed dose, respectively. The three rotational IMRT plans
(HT, VMAT, FFF-VMAT) had a mean PTV coverage of 96%. The max-
imum dose to the brainstemwas <54 Gy; the maximum dose to the
spinal cord was <50 Gy; the mean and median doses to the con-
tralateral parotid gland were <26 Gy and <20 Gy.
Before FFF-VMAT was performed, we compared the respective
absorbed out-of-field doses. Glass dosimeters (Chiyoda Technol.
Co., Ltd., Tokyo, Japan) were placed on the umbilicus and pubic
symphysis of an anthropomorphic phantom (The Phantom Labora-
tory, Salem, NY, USA). During actual beam delivery, surface doses
at the umbilicus and pubic symphysis and rectal doses were
measured.
Previous reports have suggested that some patient-specific lead
shielding devices could reduce the fetal dose in the setting of con-
ventional radiotherapy [7,8]. However, in this IMRT case using
rotational beams, a patient-specific shield above the patient was
not used because there were safety concerns (it might collapse
due to its own weight) and no general-purpose properties despitethe major expense involved. All three IMRT modalities satisfied the
PTV and OAR constraints. Fig. 2 presents the dose distributions.
The results of the phantom study are summarized in Fig. 3.
VMAT showed large out-of-field doses due to scattered photons
from the flattening filter. HT, even with an FFF beam, produced
high abdominal and pelvic doses, mainly due to a comparably lar-
ger number of MUs [9]. Depending on reduced scatter from the
flattening filter and less head leakage associated with more effi-
cient x-ray generation than conventional VMAT, FFF-VMAT
achieved the lowest fetal exposure during beam delivery and was
selected as the optimal modality [10]. The total fetal dose from
FFF-VMAT was estimated to be approximately 0.05 Gy [11], which
did not exceed the 0.1 Gy limit set by the ICRP [12]. The patient and
her family consented to the treatment.
2.2. Treatment and course
Glass dosimeters on the patient’s ventral surface and in the rec-
tum revealed that the observed doses were lower than the phan-
tom doses (Fig. 3). At this time, the patient’s weight was 53 kg
and height was 160 cm. The final fetal dose of 0.03 Gy (886 lGy
per fraction) was below the threshold value associated with cogni-
tive abnormalities and physical malformations [11,13,14].
Although a second course of cisplatin was cancelled due to
grade 4 neutropenia, the planned course of radiotherapy was com-
pleted with only two days’ interruption. Non-hematologic acute
toxicities included grade 2 mucositis and dysgeusia.
A healthy female infant was born vaginally at 37 weeks’ gesta-
tion. Unfortunately, the tumor recurred in the patient’s lung and
pleura 3 months after POCRT (1 week after vaginal delivery) with-
out any locoregional recurrence. Despite pleural drainage and sal-
vage chemotherapy, the patient died from lung metastases
6 months after radiotherapy. Her child was vigorous and had no
complications at the last follow-up at 2 years old. To assess for pos-
sible cognitive or growth impairment and the risk of developing a
malignancy, long-term follow-up is ongoing.
3. Discussion and conclusions
Obviously, pregnant women should avoid radiation therapy
until post parturition since radiation could cause harm the fetus.
Given the urgency of the high risk of recurrence, and the patient’s
being in the second trimester of pregnancy, the risk of inducing
radiation damage to the fetus was considered to be low and the
need for immediate radiotherapy to be uppermost. With respect
to cisplatin, the second trimester also poses less risk than the first
trimester [12]. According to a previous report on peripartum com-
plications and immediate fetal outcome, chemotherapy can be
Fig. 2. Treatment plans for helical tomotherapy (HT), volumetric arc therapy (VMAT), and flattening filter-free VMAT (FFF-VMAT). Representative dose distribution with
66 Gy (red), 60 Gy (yellow), and 54 Gy (blue) isodoses. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
Fig. 3. Out-of-field dose per fraction for helical tomotherapy (HT), volumetric arc
therapy (VMAT), and flattening filter-free VMAT (FFF-VMAT). Horizontal axis shows
the distance [cm] from the edge of the planning target volume. Rectal doses are
shown as ‘‘patient rectum (FFF-VMAT).” Distances of 40 cm and 62.5 cm correspond
to the umbilicus and pubic symphysis, respectively, on the phantom. Distances of
32 cm and 55 cm correspond to the umbilicus and pubic symphysis, respectively, of
the patient.
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pregnancy [15]. After the multidisciplinary meeting, we decide to
deliver POCRT to her.
In this pre-treatment assessment, we did not test 3-dimensional
conformal radiotherapy or opposing fields with/without wedges for
less scattering due to less primary fluence. We wished to administer
IMRT to the patient because of its reduced rate of side effects such asxerostomia. If an unacceptable fetal dose had been calculated for
IMRT, we would have had to consider 2- or 3-dimensional RT tech-
niques. However, in our assessment, FFF-VMAT would deliver a
low fetal dose without unacceptable doses to the organs at risk. In
FFF-VMAT, the removal of the flattening filter reduced the out-of-
field dose near the treatment field because of decreased collimator
scatter, relative to the usual VMAT technique with the filter. In FFF-
VMAT, the removal of the flattening filter reduced the out-of-field
dose because of decreased collimator scatter, relative to the usual
VMAT technique with the filter. As for HT, regardless of using FFF
beams, the more-than-expected scattered radiation were detected.
This could be due to the shielding in its accelerator design, the
small-bore size of HT, and its longer beam-on time than VMAT.
In summary, the fetal exposure to radiation during FFF-VMAT
was exceedingly low, compared to the other rotational IMRT
techniques. Therefore, we identified FFF-VMAT as a good choice
for pregnant patients needing radiation therapy, at least in the
head and neck region. However, the accuracy of the findings
might not be representative of the entire pregnant population,
and it is therefore still necessary to perform accurate model
experiments in each case. To our knowledge, this is the first
report of a successful live birth in a patient with locally advanced
tongue cancer who successfully underwent postoperative FFF-
VMAT as part of POCRT.Declarations
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